Natural history and management of HFE-hemochromatosis

Seminars in Liver Disease

Volumn 31, Issue 3, 2011, Pages 293-301

  Gan, Eng K ^a,b   Powell, Lawrie W ^c,d   Olynyk, John K ^a,b,e,f  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f CURTIN UNIVERSITY   (Australia)

Author keywords

diagnosis; hemochromatosis; HFE; management; modifiers; Natural history; penetrance

Indexed keywords

ALCOHOL; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; CYSTEINE; FERRITIN; HEMOJUVELIN; HEPCIDIN; HISTIDINE; HYALURONIC ACID; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR 2;

ALCOHOL CONSUMPTION; ANALGESIA; ARTHRALGIA; ARTHRITIS; BODY BURDEN; BREAST CANCER; CANCER SCREENING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOMYOPATHY; CITRUS FRUIT; COLORECTAL CANCER; DIETARY INTAKE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FERRITIN BLOOD LEVEL; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HEART FAILURE; HEMOCHROMATOSIS; HEREDITY; HISTORY; HOMOZYGOTE; HUMAN; INFLAMMATION; IRON OVERLOAD; JOINT PROSTHESIS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOGENESIS; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; VITAMIN SUPPLEMENTATION;

ANTIMICROBIAL CATIONIC PEPTIDES; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MEMBRANE PROTEINS; PHLEBOTOMY;

EID: 80052652791     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1286060     Document Type: Review

References (105)

1. Feder J N., Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996 13 4 399-408 (Pubitemid 26256612)
2. Merryweather-Clarke A T., Pointon J J., Shearman J D., Robson K J. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997 34 4 275-278 (Pubitemid 27208030)
3. European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010 53 1 3-22
4. Whitlock E P., Garlitz B A., Harris E L., Beil T L., Smith P R. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006 145 3 209-223 (Pubitemid 46780566)
5. Wood M J., Powell L W., Ramm G A. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008 111 9 4456-4462
6. Glycosurie T A. Diabete sucre. Clinique medicale de l'Hotel-Dieu de Paris. Vol. 2. 2nd ed. Paris J.B. Bailiere 1865 663-698
7. Von Recklinghausen F D. Uber haemochromatose. Tagll Versamml Natur Artze Heidelberg. 1889 324-325
8. Sheldon J H. Hemochromatosis. London Oxford University Press 1935
9. Laufberger V. Sur la cristallisation de la ferritine. Bull Soc Chim Biol (Paris) 1937 19 1575-1582
10. Sherlock S. Aspiration liver biopsy-Technique and diagnostic application. Lancet 1945 249 397-401
11. Davis W D. Jr, Laurens H Jr. Correlation of results of liver function tests and liver biopsy in hepatic disease. South Med J 1950 43 3 217-223
12. Davis W D. Jr, Arrowsmith W R. The effect of repeated phlebotomies in hemochromatosis; report of three cases. J Lab Clin Med 1952 39 4 526-532
13. Finch S C., Finch C A. Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis. Medicine (Baltimore) 1955 34 4 381-430
14. Simon M, Pawlotsky Y, Bourel M, Fauchet R, Genetet B. [Letter: Idiopathic hemochromatosis associated with HL-A 3 tissular antigen]. Nouv Presse Med 1975 4 19 1432
15. Leggett B A., Halliday J W., Brown N N., Bryant S, Powell L W. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990 74 4 525-530 (Pubitemid 20122757)
16. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch H J., Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985 313 20 1256-1262 (Pubitemid 16217048)
17. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996 110 4 1107-1119 (Pubitemid 26113751)
18. Beutler E, Gelbart T, West C et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996 22 2 187-194 discussion 194a-194b (Pubitemid 26397324)
19. Bacon B R., Olynyk J K., Brunt E M., Britton R S., Wolff R K. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999 130 12 953-962 (Pubitemid 29283985)
20. Sánchez M, Bruguera M, Bosch J, Rodés J, Ballesta F, Oliva R. Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol 1998 29 5 725-728 (Pubitemid 28505928)
21. Bacon B, Adams P C., Kowdley K V. et al. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011 54 1 328-343
22. Asberg A, Hveem K, Thorstensen K et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001 36 10 1108-1115 (Pubitemid 32801699)
23. Beutler E, Felitti V J., Koziol J A., Ho N J., Gelbart T. Penetrance of 845GA (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002 359 9302 211-218 (Pubitemid 34113819)
24. Delatycki M B., Allen K J., Nisselle A E. et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005 366 9482 314-316 (Pubitemid 41019421)
25. Olynyk J K., Hagan S E., Cullen D J., Beilby J, Whittall D E. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc 2004 79 3 309-313 (Pubitemid 38269232)
26. Andersen R V., Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard B G. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004 103 8 2914-2919 (Pubitemid 38451659)
27. Allen K J., Gurrin L C., Constantine C C. et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008 358 3 221-230
28. Gurrin L C., Osborne N J., Constantine C C. et al, HealthIron Study Investigators. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 2008 135 6 1945-1952
29. Gurrin L C., Bertalli N A., Dalton G W. et al, HealthIron Study Investigators. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009 50 1 94-101
30. Constantine C C., Gurrin L C., McLaren C E. et al, HealthIron Investigators. SNP selection for genes of iron metabolism in a study of genetic modifiers of hemochromatosis. BMC Med Genet 2008 9 18
31. Constantine C C., Anderson G J., Vulpe C D. et al. A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis. Br J Haematol 2009 147 1 140-149
32. Benyamin B, McRae A F., Zhu G et al. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am J Hum Genet 2009 84 1 60-65
33. Osterreicher C H., Datz C, Stickel F et al. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 2005 31 2 142-148 (Pubitemid 40910230)
34. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004 103 7 2835-2840 (Pubitemid 38393047)
35. Le Gac G, Scotet V, Ka C et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004 13 17 1913-1918 (Pubitemid 39214339)
36. Milet J, Dehais V, Bourgain C et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet 2007 81 4 799-807 (Pubitemid 47603057)
37. Van Vlierberghe H, Langlois M, Delanghe J et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 2001 35 6 707-711 (Pubitemid 34717660)
38. Moirand R, Lescoat G, Delamaire D et al. Increase in glycosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawal. Alcohol Clin Exp Res 1991 15 6 963-969
39. Cade J E., Moreton J A., O'Hara B et al. Diet and genetic factors associated with iron status in middle-aged women. Am J Clin Nutr 2005 82 4 813-820 (Pubitemid 43779695)
40. Milward E A., Baines S K., Knuiman M W. et al. Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin Proc 2008 83 5 543-549 (Pubitemid 351717001)
41. Fletcher L M., Dixon J L., Purdie D M., Powell L W., Crawford D H. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002 122 2 281-289 (Pubitemid 34116981)
42. Adams P C., Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 1996 23 4 724-727 (Pubitemid 26111984)
43. Diwakaran H H., Befeler A S., Britton R S., Brunt E M., Bacon B R. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002 36 5 687-691 (Pubitemid 34499407)
44. Powell E E., Ali A, Clouston A D. et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005 129 6 1937-1943 (Pubitemid 41772971)
45. Barton J C., Barton J C., Acton R T. Longer survival associated with HLA-A*03, B*14 among 212 hemochromatosis probands with HFE C282Y homozygosity and HLA-A and -B typing and haplotyping. Eur J Haematol 2010 85 5 439-447
46. Shi Z, Johnstone D, Talseth-Palmer B A. et al. Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer 2009 125 1 78-83
47. Osborne N J., Gurrin L C., Allen K J. et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010 51 4 1311-1318
48. Zacharski L R., Chow B K., Howes P S. et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008 100 14 996-1002 (Pubitemid 352019800)
49. Chua A C., Klopcic B, Lawrance I C., Olynyk J K., Trinder D. Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol 2010 16 6 663-672
50. Adams P C., Barton J C. Haemochromatosis. Lancet 2007 370 9602 1855-1860 (Pubitemid 350180034)
51. Olynyk J K., Trinder D, Ramm G A., Britton R S., Bacon B R. Hereditary hemochromatosis in the post-HFE era. Hepatology 2008 48 3 991-1001
52. Pietrangelo A. Hereditary hemochromatosisa new look at an old disease. N Engl J Med 2004 350 23 2383-2397
53. Andrews N C. Forging a field: the golden age of iron biology. Blood 2008 112 2 219-230
54. Fleming R E., Britton R S., Waheed A, Sly W S., Bacon B R. Pathogenesis of hereditary hemochromatosis. Clin Liver Dis 2004 8 4 755-773 vii (Pubitemid 39311143)
55. Park C H., Valore E V., Waring A J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001 276 11 7806-7810
56. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002 29 3 327-335
57. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006 91 6 727-732 (Pubitemid 44014536)
58. Ganz T. Iron homeostasis: fitting the puzzle pieces together. Cell Metab 2008 7 4 288-290 (Pubitemid 351467393)
59. Pak M, Lopez M A., Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006 108 12 3730-3735 (Pubitemid 44864551)
60. Piperno A, Galimberti S, Mariani R et al, HIGHCARE investigators. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood 2011 117 10 2953-2959
61. Nicolas G, Bennoun M, Porteu A et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002 99 7 4596-4601 (Pubitemid 34286030)
62. Milward E A., Trinder D, Wilcox C E., Britton R S., Ramm G A., Olynyk J K. Is HFE involved in increased hepcidin expression and hypoferremia in inflammation and anemia of chronic disease? Hepatology 2005 41 4 936-938 (Pubitemid 40462956)
63. Trinder D, Ayonrinde O T., Olynyk J K. HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology 2008 134 1 348-351 (Pubitemid 350309353)
64. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009 122 2-3 78-86
65. Olynyk J K., Cullen D J., Aquilia S, Rossi E, Summerville L, Powell L W. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999 341 10 718-724 (Pubitemid 29407371)
66. McLaren C E., McLachlan G J., Halliday J W. et al. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology 1998 114 3 543-549 (Pubitemid 28141200)
67. Bacon B R. Screening for hemochromatosis. Arch Intern Med 2006 166 3 269-270 (Pubitemid 43244313)
68. Bomford A. Genetics of haemochromatosis. Lancet 2002 360 9346 1673-1681 (Pubitemid 35379742)
69. Adams P C., Reboussin D M., Leiendecker-Foster C et al. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) study. Clin Chem 2005 51 6 1048-1052 (Pubitemid 40740896)
70. Powell L W., Dixon J L., Ramm G A. et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006 166 3 294-301 (Pubitemid 43244317)
71. Power T E., Adams P C., Barton J C. et al. Psychosocial impact of genetic testing for hemochromatosis in the HEIRS Study: a comparison of participants recruited in Canada and in the United States. Genet Test 2007 11 1 55-64 (Pubitemid 46557358)
72. Hall M A., Barton J C., Adams P C. et al. Genetic screening for iron overload: no evidence of discrimination at 1 year. J Fam Pract 2007 56 10 829-834 (Pubitemid 350072156)
73. Camaschella C, Poggiali E. Rare types of genetic hemochromatosis. Acta Haematol 2009 122 2-3 140-145
74. Kaneko Y, Miyajima H, Piperno A et al. Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. J Gastroenterol 2010 45 11 1163-1171
75. Olynyk J K., St Pierre T G., Britton R S., Brunt E M., Bacon B R. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 2005 100 4 837-841 (Pubitemid 40592376)
76. St Pierre T G., Clark P R., Chua-anusorn W et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005 105 2 855-861 (Pubitemid 40070775)
77. Olsson K S. Iron stores in normal men and male blood donors. As measured by desferrioxamine and quantitative phlebotomy. Acta Med Scand 1972 192 5 401-407
78. Adams P C. Role of genetic testing and liver biopsy in the diagnosis of hemochromatosis. Curr Gastroenterol Rep 1999 1 1 27-29
79. Crawford D HG, Murphy T L., Ramm L E. et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009 49 2 418-425
80. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008 48 5 835-847
81. Adhoute X, Foucher J, Laharie D et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol 2008 32 2 180-187 (Pubitemid 351635694)
82. Davis W D. Jr, Arrowsmith W R. The treatment of hemochromatosis by massive venesection. Ann Intern Med 1953 39 4 723-734
83. Bismuth M, Peynaud-Debayle E. Management of patients with HFE-related haemochromatosis (Type 1 haemochromatosis). 2005; Available at: http://www.has-sante.fr/portail/jcms/c-432802/management-of-patients-with-hfe- related-haemochromatosis-type-1-haemochromatosis Accessed March 10, 2011
84. Brissot P, de Bels F. Current approaches to the management of hemochromatosis. Hematology (Am Soc Hematol Educ Program) 2006 36-41
85. Barton J C., Bottomley S S. Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis. Am J Hematol 2000 65 3 223-226
86. Adams P C., Speechley M, Kertesz A E. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991 101 2 368-372
87. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976 45 180 611-623
88. Phatak P, Brissot P, Wurster M et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010 52 5 1671-1779
89. Brandhagen D J. Liver transplantation for hereditary hemochromatosis. Liver Transpl 2001 7 8 663-672 (Pubitemid 32771464)
90. Crawford D HG, Fletcher L M., Hubscher S G. et al. Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis. Hepatology 2004 39 6 1655-1662 (Pubitemid 38702667)
91. Brock J H., Mulero V. Cellular and molecular aspects of iron and immune function. Proc Nutr Soc 2000 59 4 537-540 (Pubitemid 32002984)
92. Dar F S., Faraj W, Zaman M B. et al. Outcome of liver transplantation in hereditary hemochromatosis. Transpl Int 2009 22 7 717-724
93. Yu L, Ioannou G N. Survival of liver transplant recipients with hemochromatosis in the United States. Gastroenterology 2007 133 2 489-495 (Pubitemid 47187357)
94. Murphy C J., Oudit G Y. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail 2010 16 11 888-900
95. Liu P, Olivieri N. Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther 1994 8 1 101-110 (Pubitemid 24164805)
96. Easley R M. Jr, Schreiner B F. Jr, Yu P N. Reversible cardiomyopathy associated with hemochromatosis. N Engl J Med 1972 287 17 866-867
97. Arnold J M., Liu P, Demers C et al, Canadian Cardiovascular Society. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006 22 1 23-45
98. Olivieri N F., Liu P P., Sher G D. et al. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. N Engl J Med 1994 330 16 1125-1127
99. Carroll G J., Breidahl W H., Bulsara M K., Olynyk J K. Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. Arthritis Rheum 2011 63 1 286-294
100. Carlsson A. Hereditary hemochromatosis: a neglected diagnosis in orthopedics: a series of 7 patients with ankle arthritis, and a review of the literature. Acta Orthop 2009 80 3 371-374
101. Kaltwasser J P., Werner E, Schalk K, Hansen C, Gottschalk R, Seidl C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 1998 43 5 699-704 (Pubitemid 28520107)
102. Nienhuis A W. Vitamin C and iron. N Engl J Med 1981 304 3 170-171 (Pubitemid 11163005)
103. Fracanzani A L., Conte D, Fraquelli M et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001 33 3 647-651 (Pubitemid 32185227)
104. Kallianpur A R., Hall L D., Yadav M et al. Increased prevalence of the HFE C282Y hemochromatosis allele in women with breast cancer. Cancer Epidemiol Biomarkers Prev 2004 13 2 205-212 (Pubitemid 38222550)
105. Kovac S, Anderson G J., Baldwin G S. Gastrins, iron homeostasis and colorectal cancer. Biochim Biophys Acta 2011 1813 5 889-895